Recursion Pharmaceuticals, Inc. upgraded to Buy on promising REC-4881 data, strong partnerships, and AI-driven drug discovery ...
Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...
RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...
Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...
A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.
The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...
The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...
The reported valuation aligns with where Manus had been headed before Meta intervened. The company had been raising new funds ...
AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback